Market Signal Briefing

Pursuit Attractions and Hospitality, Inc. (PRSU) Q4 2025 Earnings Call Transcript

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

Commentary

Expect Gold, Treasuries, and Other Safe Assets to Rise After Iran Attack. Why Investors Shouldn’t Panic.

By

Matt Gertken

Be sure: The U.S. and Israel are pursuing full regime change in Iran. Israel has said their joint attack Saturday killed Supreme Leader Ali Khamenei, according to The Wall Street Journal. Other Iranian leaders remain prime targets.

MOBICO GROUP PLC (NXPGF) Q4 2025 Earnings Call Transcript

February 28, 2026 16:23 ET  | Source: APEX Tech Acquisition, Inc.

New York, New York, Feb. 28, 2026 (GLOBE NEWSWIRE) -- APEX Tech Acquisition Inc., a blank check company incorporated in the Cayman Islands as an exempted company (the “Company”), today announced the closing of its initial public offering of 11,197,131 units, including partial exercise of an over-allotment option, at $10.00 per unit for aggregate gross proceeds to the Company of $111,971,310. The units began trading on The New York Stock Exchange (“NYSE”) on February 26, 2026 under the ticker symbol “TRADU.” Each unit consists of one ordinary share and one right to receive one-fourth (1/4) of one ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and the rights are expected to be traded on NYSE under the symbols “TRAD” and “TRADR,” respectively.

A.G.P./Alliance Global Partners acted as the sole book-running manager for the offering.

Venture Bridge Legal served as the U.S. counsel to the Company and Robinson & Cole LLP served as the U.S. counsel to the representative of the underwriters in this offering.

A registration statement on Form S-1 relating to the securities, as amended (File No. 333-291936) was previously filed with the Securities and Exchange Commission ("SEC") and declared effective on February 25, 2026. This offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus may be obtained on the SEC’s website at http://www.sec.gov. Electronic copies of the prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. No securities regulatory authority has either approved or disapproved of the contents of this press release.

About APEX Tech Acquisition Inc.

The Company is a blank check company incorporated in the Cayman Islands as an exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to conduct a search for target businesses without being limited to a particular industry.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering, the underwriters’ exercise of over-allotment option, the anticipated use of the net proceeds thereof and the Company’s search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov.The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
APEX Tech Acquisition Inc.
Attn: Shaoren Liu
E-mail: [email protected]

The streaming and entertainment industry just witnessed one of its most high-stakes megadeals ever, stunning industry observers. Not only is it historic in its size, but it is also predicted to disrupt Hollywood and the media business as we know it. 

After years of Warner Bros. Discovery struggling under the weight of billions of dollars in debt, compounded by declining cable viewership and fierce competition from streaming platforms, the company has been considering major strategic changes, including selling its entertainment assets to one of its rivals.

Several major players saw the potential in acquiring the media giant and in December, Netflix announced it would acquire WBD’s studios and streaming for $82.7 billion.

But in a surprise eleventh-hour move this month, it now looks like the David Ellison-run Paramount will actually be the winner of this bidding war, offering $111 billion to acquire all of Warner Bros. Discovery’s assets, including its studios, HBO, streaming platforms, games, and TV networks such as CNN and HGTV. Paramount was itself recently acquired by Ellison with significant support from his father, the Oracle chairman, world’s sixth-richest person, and major Trump donor Larry Ellison.

Paramount’s offer still awaits formal approval from WBD’s board of directors, and any potential agreement may also face pressure from regulators.

Let’s break down exactly what is happening, what’s at stake, and what could come next. 

What has happened so far? ​This all started back in October when Warner Bros. Discovery (WBD) revealed it was exploring a potential sale after receiving unsolicited interest from several major players in the industry.

Techcrunch event

Boston, MA | June 9, 2026

​The bidding process quickly became competitive, and Paramount and Comcast emerged as serious contenders, with Paramount initially viewed as the frontrunner. 

However, WBD’s board eventually determined that an offer from the streaming giant Netflix was the most attractive. Netflix offered $82.7 billion for just Warner’s film, television, and streaming assets.

Thus began the bidding war. Paramount believed its bid, of approximately $108 billion for all of Warner’s assets, was superior to Netflix’s offer that focused on just the studios and streaming. To sweeten its deal, Netflix amended its agreement in January to an all-cash offer at $27.75 per share of Warner Bros. Discovery, further reassuring investors and paving the way for the deal to proceed.

​Paramount persisted in its attempts to acquire WBD. Still, the Warner board repeatedly rejected its offers, citing concerns about Paramount’s heavy debt load and the increased risk associated with its proposal, including concern over the suite of investors bankrolling Paramount’s bid, which includes Saudi, Qatari, and Abu Dhabi sovereign wealth funds. The board noted that Paramount’s offer would have left the combined company burdened with $87 billion in debt, a risk they were unwilling to take at the time.

In January, Paramount filed a lawsuit seeking more information about the Netflix deal. A month later, the company sought to sweeten its deal by announcing it would offer a $0.25 per share “ticking fee” to WBD shareholders for each quarter the deal fails to close by December 31, 2026. It also said it would pay the $2.8 billion breakup fee if Warner backs out of its deal with Netflix.

Then, in a final attempt to secure a deal, Paramount increased its offer to $31 per share in February. This prompted the WBD board to prolong discussions with Paramount regarding a potential agreement, considering it as a superior offer. Netflix declined to increase its bid and withdrew from the negotiations.

“The transaction we negotiated would have created shareholder value with a clear path to regulatory approval,” Netflix co-CEOs Ted Sarandos and Greg Peters said in a statement on Feb. 26. “However, we’ve always been disciplined, and at the price required to match Paramount Skydance’s latest offer, the deal is no longer financially attractive, so we are declining to match the Paramount Skydance bid.”

In addition to the billions Paramount already holds in debt, the company is also set to assume the approximately $33 billion in debt Warner Bros. Discovery holds under the agreement. The deal will be backed by a $54 billion debt commitment from Bank of America Merrill Lynch, Citi, and Apollo Global Management, as well as $45.7 billion in equity from Larry Ellison.

Regulatory hurdles and other concerns Image Credits:Bryce Durbin/TechCrunch In addition to the assumption of substantial debt posing a significant financial burden, Paramount faces several other hurdles in its deal with WBD that could impact the success of the transaction. 

For one, Ellison has warned about significant job reductions that are expected in the near future. There have already been widespread concerns among critics about potential job losses and lower wages.

Ellison is also a controversial figure in the industry, and his ownership of CBS News has been seen as sympathetic and supportive of the administration of Donald Trump, of whom his father, Larry Ellison, is a major donor. Under Ellison’s ownership of Paramount, reporting critical of the administration has been shelved or received increased scrutiny from Ellison or his appointed head of CBS News, the conservative provocateur Bari Weiss.

This has led to some concern among employees at Warner-owned CNN. Trump has personally sought concessions from news divisions critical of him, including a $16 million settlement from CBS, before his FCC would approve the Ellison takeover of Paramount. Before Netflix bowed out of the deal, Trump pressured the company to fire the former Biden White House official Susan Rice from its board. He has publicly stated his intentions to bring CNN to heel under new owners.

Regulatory scrutiny is another hurdle. Such a large-scale merger has attracted attention from lawmakers.

For instance, California Attorney General Rob Bonta said in a statement on February 26 that “these two Hollywood titans have not cleared regulatory scrutiny — the California Department of Justice has an open investigation, and we intend to be vigorous in our review.”

A day before Netflix backed out, it was revealed that a coalition of 11 state attorneys general urged the U.S. Department of Justice (DOJ) to review the merger under concerns it will stifle competition and increase subscription prices. This comes months after U.S. senators Elizabeth Warren, Bernie Sanders, and Richard Blumenthal voiced their concerns to the Justice Department’s Antitrust Division, warning that such a massive merger could have serious consequences for consumers and the industry at large. The senators argue that the merger could give the new media giant excessive market power, enabling it to raise prices for consumers and stifle competition.

That said, Ellison’s father, the Oracle chairman Larry Ellison, is a significant Trump donor and has close ties to the Trump administration. His deal to acquire Paramount last year cleared quickly after acquiescing to c

When is the deal expected to close? The deal is not yet final.

Initially, a deal with Netflix was expected to lead to a stockholder vote around April, with the deal anticipated to close within 12 to 18 months following that vote. However, the transition to the Paramount deal will likely create a new timeline for approval. Plus, regulatory approvals are still pending, and scrutiny could shape the final outcome. 

Stay tuned…

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to demonstrate such ability and reduce testing variability that could interfere with such a result.

The lawsuit claims that defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of setrusumab's potential, as well as the true risk inherent in the study protocols put forth; notably, that while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise, that the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. The lawsuit claims that such statements absent these material facts caused Ultragenyx shareholders to purchase Ultragenyx securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285695

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The joint U.S. and Israeli attack on OPEC member Iran risks a major oil supply disruption in the Middle East that, in a worst-case scenario, could trigger a global economic recession.

Iran is the fourth-largest oil producer in OPEC at just over 3 million barrels per day in January. The Islamic Republic shares a coastline with the Strait of Hormuz, the world's most important waterway for the global oil trade.

The oil market has long shrugged off the risk of an oil supply disruption in the Middle East. Traders are underestimating the threat that Iranian retaliation to the U.S. attack poses to the market, said Bob McNally, a former White House energy advisor to former President George W. Bush.

"This is the real deal," said McNally, founder and president of Rapidan Energy. Crude oil future prices will likely rise by $5 to $7 per barrel when trading opens at 6 p.m. ET Sunday as the market prices in some risk, he said.

On Friday, Brent crude prices settled at $72.48 a barrel, up $1.73, or 2.45%, while U.S. West Texas Intermediate crude finished at $67.02 a barrel, up $1.81, or 2.78%.

Iran could try to scare President Donald Trump by making the Strait of Hormuz unsafe for commercial traffic, which could spike oil prices above $100 per barrel, McNally said. The market does not appreciate the fact that Tehran has large stockpiles of mines and short-range missiles that could seriously disrupt traffic in the waterway, he said.

More than 14 million barrels per day flowed through the Strait in 2025, or a third of the world's total seaborne crude exports, according to data from energy consulting firm Kpler. About three-quarters of those barrels went to China, India, Japan and South Korea. China, the world's second-largest economy, receives half of its crude imports from the Strait.

"A prolonged closure of the Strait of Hormuz is a guaranteed global recession," McNally said.

More than 20 million barrels of crude have been loaded for export today in the Gulf from Saudi Arabia, Iraq, the United Arab Emirates, Kuwait and Qatar, said Matt Smith, an oil analyst at Kpler. Some tankers have been observed diverting from passing through the strait, Smith said.

The world's spare oil capacity comes from the Gulf states and would be unable to pass through the strait in the event of a closure, effectively sealing it off from the market, McNally said. About 20% of the world's liquid natural gas exports also flow through the strait, mostly from Qatar, and would be unable to be replaced, he said.

"What you would see is hoarding, especially by Asian countries that were big importers of oil and gas when they realized that Hormuz is closed," McNally said. "You would see the mother of all bidding wars."

Oil prices would have to rise high enough to trigger an economic downturn that reduces demand to balance the market, the analyst said. "There just isn't enough discretionary or elastic demand for oil," he said.

Only a small fraction of the crude that passes through the strait might be able to be redirected, McNally said. The Saudis have a pipeline that spans the country from the East to its Western coast on the Red Sea. The UAE has a pipeline that terminates at the Gulf of Oman, bypassing the Strait of Hormuz.

Iran has launched missile strikes on U.S. bases in Qatar, Kuwait, the UAE and Bahrain, according to state media reports. These attacks could affect traffic through the Strait of Hormuz, said Tom Kloza, principal at oil and gas consulting firm Kloza Advisors.

"The attack by Iran on other neighbors in the Persian Gulf changes the calculus and the extent of the assaults put pressure on insurers to either aggressively raise tanker rates for Strait of Hormuz travel or balk at underwriting any traffic," Kloza said.

The Trump administration could tap the Strategic Petroleum Reserve if oil prices spike, said Kevin Book, managing director of Research at ClearView Energy Partners. The reserve currently has an inventory of about 415 million barrels, according to data from the Department of Energy.

"But we'll say it again: in supply crises, duration matters. Scale does, too," Book told clients in a note Saturday. "A full Hormuz crisis could outstrip offsets provided by strategic stocks in the U.S. and International Energy Agency (IEA) members."

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alight, Inc. (NYSE: ALIT) resulting from allegations that Alight may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Alight securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=54542 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On February 19, 2026, before the market opened, Alight issued a press release entitled "Alight Reports Fourth Quarter and Full Year 2025 Results". Among other metrics, the release stated disclosed results of "[g]ross profit of $240 million and gross profit margin of 36.8%, compared to $271 million and 39.9% in the prior year period, respectively, and adjusted gross profit of $272 million and adjusted gross profit margin of 41.7%, compared to $300 million and 44.1% in the prior year period, respectively[.]"

On this news, Alight stock fell 38.2% on February 19, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285707

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

National Bank of Greece S.A. (NBGRY) Q4 2025 Earnings Call February 27, 2026 3:30 AM EST

Company Participants

Paul Mylonas - CEO & Executive Director
Christos Christodoulou - GM & Group CFO

Conference Call Participants

Benjamin Caven-Roberts - Goldman Sachs Group, Inc., Research Division
Mehmet Sevim - JPMorgan Chase & Co, Research Division
Gabor Kemeny - Bernstein Autonomous LLP
Robert Brzoza - Biuro Maklerskie PKO Banku Polskiego, Research Division
Ilija Novosselsky - BofA Securities, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. I am Gelly, your Chorus Call operator. Welcome, and thank you for joining the National Bank of Greece conference call to present and discuss the full year 2025 financial results. At this time, I would like to turn the conference over to Mr. Pavlos Mylonas, CEO of National Bank of Greece. Mr. Mylonas, you may now proceed.

Paul Mylonas
CEO & Executive Director

Good morning, everyone. Welcome to our fourth quarter 2025 financial results call. I'm joined by Christos Christodoulou, the Group CFO; and Greg Papagrigoris, Group Head of IR. After my introductory remarks, Christos will go into more detail on our financial performance, and then we will turn to questions and answers.

As usual, I will refer to Greece's macroeconomic developments first, then turn to our fourth quarter results. and I will conclude with our guidance for the next 3 years, 2026, 2028. So let's begin. The Greek economy remains on a steady, upward trajectory, notwithstanding persistent global volatility amid intensifying geopolitical tensions with the EU appearing particularly exposed to ongoing structural shifts.

Within this challenging environment, Greece has delivered not only a resilient performance, but also a more balanced and higher quality growth mix. Indeed, the recovery has become more broad-based with manufacturing, high value-added services and construction increasingly complementing tourism. The economy remains attractive to investment as gross fixed capital

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Lakeland Industries, Inc. (NASDAQ: LAKE) between December 1, 2023 and December 9, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2026.

SO WHAT: If you purchased Lakeland securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lakeland class action, go to https://rosenlegal.com/submit-form/?case_id=50020 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lakeland was experiencing significant, sustained issues with its Pacific Helmets and Jolly businesses, including, inter alia, shipping-related delays, production issues, and slower than expected rollout of new products; (2) accordingly, defendants overstated the anticipated and actual positive impact of these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (3) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification delays, and material flow issues in its acquired businesses; (4) accordingly, defendants overstated the strength of their tariff mitigation measures and "small, strategic, and quick" ("SSQ") M&A strategy; (5) as a result of all the foregoing issues, defendants' financial guidance was unreliable; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lakeland class action, go to https://rosenlegal.com/submit-form/?case_id=50020 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285740

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Shares of Cava Group (CAVA 2.97%) surged after the Mediterranean-themed restaurant operator issued upbeat guidance with its fourth-quarter earnings report. The stock is up more about 45% year to date but still down about 15% over the past year.

Let's dig into the company's latest results and prospects to see if the stock's momentum can continue.

Today's Change

(

-2.97

%) $

-2.52

Current Price

$

82.22

An upbeat outlook 2025 was a difficult year for Cava stock, with its shares getting nearly cut in half. The biggest reason for this was that its same-store sales growth slowed dramatically starting in Q2. However, that was largely due to the lapping of the introduction of its highly popular grilled steak option in 2024.

With those tough comparisons now behind the company, it forecasted 3% to 5% comparable-restaurant sales growth for 2026. That's a nice jump compared to the last three quarters of 2025, which ended with it only reporting a 0.5% increase in Q4.

Overall revenue for Q4 climbed 21% year over year to $272.8 million. It opened 24 new restaurants in the quarter, bringing its total to 439 locations, a nearly 20% increase compared to a year ago.

After entering a few new Midwest markets in 2025, the company continues to expand in the region, with planned openings in Cincinnati, St. Louis, Columbus, and Minneapolis in 2026. Overall, it is looking to open between 74 and 76 new locations in fiscal 2026. Its goal remains to reach at least 1,000 restaurants by 2032.

Its restaurant-level margins (RLMs) came in at 21.4% in the quarter, down from 22.4% a year ago, and were 24.4% for the full year. RLMs measure how profitable a chain's individual restaurants are before corporate costs. It expects a 2026 RLM of between 23.7% and 24.2%.

On the profitability front, Cava's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 3% year over year to $25.8 million. The company also generated $184.8 million in operating cash flow for the year and free cash flow of $26.1 million.

Image source: Getty Images.

Is the stock still a buy? Cava has robust average unit volumes (AUVs) of nearly $3 million with strong RLMs, as it uses a similar strategy to Chipotle, with minimal ingredients that can be used in a multitude of combinations. Meanwhile, with fewer than 450 locations, it has one of the best expansion stories in the restaurant industry, as it moves into new markets and infills existing ones.

Given the expansion opportunity still in front of it, Cava is an interesting growth story. However, after this surge, I think the stock has gotten way ahead of itself. It has a market cap of $9.8 billion and 439 locations. That's valuing each of its locations, which average just under $3 million in yearly sales, at $22.3 million per restaurant location. That's way too high.

AFC Energy plc (AFGYF) Q4 2025 Earnings Call February 27, 2026 9:00 AM EST

Company Participants

John Wilson - CEO & Executive Director
Karl Bostock - CFO & Executive Director

Presentation

Unknown Executive

Good afternoon, ladies and gentlemen, and welcome to the AFC Energy plc Full Year Results Investor Presentation. [Operator Instructions] Given the significant attendance on today's call, the company will not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and will publish responses where it's appropriate to do so.

Before we begin, we'd like to submit the following poll, and I'm sure the company will be most grateful for your participation. I'd now like to hand over to the team from AFC Energy, John and Karl. Good afternoon.

John Wilson
CEO & Executive Director

Thank you. Thank you, Mark. Good afternoon, everyone, and welcome to our presentation on our full year results for the year ending 31st of October 2025. So usual disclaimer that we put up for everyone to read in their own time.

Moving on, by way of an agenda, we'll run through the business overview, talk through the strategic progress the business has made products and technology overview, what we're focusing on commercially, the results for the financial year, a short time talking about outlook, and then we will take questions from you all. So when we joined the business, and I've said this before, what we did was we really started to look at why the global hydrogen economy hadn't really kick started. And it was clear that it was being held back by cost and infrastructure challenges. So we set out on a journey to develop a business and a strategy that would unlock those challenges. So our cracker technology allows us to deal with the infrastructure and the cost and our

SummaryAbel emphasizes trust, Berkshire valuesAnalysts say Abel struck the right toneBerkshire reports declining profit for Q4, 2025Feb 28 (Reuters) - Berkshire Hathaway's (BRKa.N), opens new tab new Chief Executive Greg Abel moved to put his stamp on the conglomerate with his first annual letter to shareholders on Saturday, pledging to maintain its "fortress-like" balance sheet and uphold the values of his predecessor and mentor, Warren Buffett.

Abel, 63, said he wouldn't rush to deploy Berkshire's near-record $373.3 billion cash stake, though he said it gave the company plenty of "dry powder" and that he had no plans to begin paying dividends, which Buffett also opposed. Berkshire has not repurchased its own stock since the spring of 2024.

Make sense of the latest ESG trends affecting companies and governments with the Reuters Sustainable Switch newsletter. Sign up here.

"I recognize how you want us to succeed together, and to do so in the right way," Abel wrote in an 18-page, single-spaced letter. "My role is to ensure our liquidity levels and capital deployment remain intentional and deliberate."

Abel also paid homage to Buffett, 95, who remains chairman and goes to Berkshire's offices five days a week, calling him a "remarkable" CEO.

"Warren Buffett is arguably the greatest investor of all time, with generations benefiting from his investment acumen," Abel wrote. "To invest in Berkshire has long been a vote of trust in our founder – a trust that now rests with Berkshire."

Berkshire shares have significantly underperformed the Standard & Poor's 500 index (.SPX), opens new tab since Buffett announced unexpectedly in May he was stepping aside as CEO.

Though Abel's letter lacked Buffett's writing flair, CFRA Research analyst Cathy Seifert said it might prove reassuring to investors.

"He needed to show a degree of continuity, that the Berkshire franchise would continue despite the change in leadership, and it would be business as usual," she said. "In my opinion, he hit the mark."

The letter also signaled that Abel wouldn't upend Buffett's 60 years of work transforming Berkshire from a failing textile company into a more than $1 trillion conglomerate that owns car insurer Geico, BNSF railroad and dozens of other insurance, manufacturing, energy and retail businesses.

"If there were any doubts about whether Greg was the right individual to take the reins, the letter should dispel them," said Dan Hanson, who oversees more than $6 billion as head of the quality equity team at Neuberger Berman.

PROFIT DECLINESBerkshire also reported declining profit, after taking writedowns for its approximately 27% stakes in both Kraft Heinz (KHC.O), opens new tab and oil company Occidental Petroleum (OXY.N), opens new tab.

Fourth-quarter operating profit fell 30% to $10.2 billion as income from insurance operations such as Geico declined.

Net income fell 3% to $19.2 billion, reflecting a $4.5 billion writedown for Occidental, despite gains from equity holdings led by Apple (AAPL.O), opens new tab and American Express (AXP.N), opens new tab.

For all of 2025, operating profit fell 6% to $44.49 billion, while net income fell 25% to $66.97 billion. Buffett had long urged investors to ignore fluctuations in Berkshire's net income, which reflect accounting rules for equity investments.

Full-year revenue was essentially unchanged at $371.44 billion, and Seifert said Abel "teed up an expectation that reinsurance and commercial insurance growth may be nonexistent" in 2026."

One of Berkshire's best-known businesses, Fruit of the Loom, shed 6,000 jobs last year as revenue fell, Berkshire said.

WILDFIRE-BATTERED PACIFICORP UTILITY 'NOT A DEEP POCKET'Abel said Berkshire's culture and values will continue "in perpetuity," and signaled no changes in its decentralized structure in which its dozens of businesses operate largely without interference from the top.

He also signaled a willingness to stick around, suggesting that in 20 years he will have had "just a fraction of the tenure that Warren had."

Abel pledged to invest in durable, well-managed businesses that Berkshire understands and "avoid businesses that undermine the fabric of society or could jeopardize Berkshire's reputation."

He didn't elaborate, but Seifert said he could have been referring to artificial intelligence.

Abel acknowledged pressures on its PacifiCorp utility from litigation over Oregon and California wildfires that burned more than 500,000 acres in 2020.

Many victims blame PacifiCorp, saying it failed to shut off power lines. The utility has reached more than $2.2 billion of settlements, but faces $50 billion of additional wildfire claims. Abel said Berkshire accepts responsibility when it causes wildfires, but will fight unjustified claims in court.

"PacifiCorp is not an insurer of last resort and should not be treated as a deep pocket," Abel said. "Accountability, paired with principled opposition to unwarranted liability, is essential to preserving the regulatory compact that governs utilities."

TED WESCHLER STAYS ONAbel was more critical than Buffett of Berkshire businesses that could perform better.

He said the performance gap between BNSF and industry-leading rivals is "too wide," while "self-inflicted" difficulties at the Shaw flooring company hurt quality and service.

"Each business is accountable to its CEO, who is expected to pursue operational excellence relentlessly and close performance gaps," Abel said, referring to Berkshire's non-insurance businesses.

Hanson, the Neuberger Berman investment manager, said: "Those are fighting words."

Berkshire has not named a chief investment officer to replace Buffett, though Abel said responsibility for equity investments "ultimately resides with me as CEO."

Abel signaled that longtime portfolio manager Ted Weschler, who manages about 6% of Berkshire's equity investments, will continue playing a "broader role" assessing significant investment opportunities and supporting Berkshire in other ways.

Reporting by Jonathan Stempel in New York, Editing by Megan Davies, Louise Heavens and Cynthia Osterman

Our Standards: The Thomson Reuters Trust Principles., opens new tab

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285749

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) CEO Corey Ruttan talked with Proactive about the company’s strong 2025 performance and ambitious growth plans for 2026, highlighting major reserve increases, production growth and dividend returns to shareholders.

Proactive: Alright welcome back inside our Proactive newsroom, and joining me now is Corey Ruttan, CEO of Alvopetro Energy Ltd. Corey it's great to see you again. How are you?

Corey Ruttan: I'm very well thank you.

The company is out with its basic numbers for 2025 and looking ahead to 2026. One figure that really jumps off the page is 79% reserve expansion. That’s a significant milestone. What went well last year?

We had a really strong year. Last year really was a breakout year for Alvopetro. We were able to significantly increase our productive capacity off the strength of results from our 100% owned Murucututu project in northeast Brazil, mostly from the success of the 183-D4 well that we brought on production in August.

Average production in 2025 was up 41% year over year to over 2,500 barrels of oil equivalent per day. We exited 2025 with a record quarter at nearly 2,900 barrels of oil equivalent per day. To start 2026, we posted another record month in January at 3,100 barrels of oil equivalent per day — up 8% from Q4 and 23% above the 2025 average.

You operate in Brazil and Canada. Let’s start with Brazil. What are the plans there for 2026?

We announced our year-end reserves, which reflected the successes of 2025. Despite producing nearly one million barrels of oil equivalent last year, 1P reserves increased 79% to over 8 million barrels of oil equivalent, representing a 485% production replacement ratio.

2P reserves increased 43% to over 13 million barrels of oil equivalent, representing a 530% production replacement ratio. On a 1P basis, net present value increased 38%, and on a 2P basis it increased 20% to nearly $400 million.

For 2026, the capital plan focuses on Brazil and Canada. In Brazil, the company is expanding field production facilities and pipeline takeaway capacity at Murucututu to accommodate growing production. Once those projects are completed, the company plans to ramp up development drilling and unlock further value.

And what about Canada?

The company added a Canadian growth platform last year. It has drilled eight wells on a gross basis, four net wells, using open hole multilateral drilling technology. All wells are now on production.

The company has earned an interest in 75 sections of prospective land and sees over 100 tier-one drilling locations, positioning it for future growth.

Growth in both regions is significant. Can you talk about your capital allocation philosophy?

The company has a disciplined and unique capital allocation model. It allocates roughly half of cash flow to organic growth and returns the other half to stakeholders.

In Q4, the company increased its dividend by 20%, including special dividends of up to US$0.12 per share, representing a yield of over 8%.

Although 2025 was a fantastic year, the company is excited about 2026 and its longer-term growth opportunities.

Quotes have been lightly edited for style and clarity

Châtillon, France, February 28, 2026

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo groupApproximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group24% of children on placebo decreased their eliciting dose between the baseline and month 12 double-blind, placebo-controlled food challenge, compared to only 6.4% of children treated with the VIASKIN® Peanut Patch DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation today at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the largest food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV’s VIASKIN® Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years.

The VITESSE study met its primary endpoint whereby VIASKIN Peanut demonstrated a statistically significant treatment effect (p<0.001), with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria* at 12 months, as compared to 14.8% of children in the placebo arm (difference in response rates = 31.8%; 95% confidence interval (CI) = (24.5, 39.0%)), exceeding the lower bound prespecified threshold of 15%.

Highlights from the data presented at AAAAI 2026:

82.8% of subjects treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least one dose, or one incremental step in a double-blind placebo-controlled food challenge, at month 12, compared to approximately 48% in the placebo group. 60.1% of the treated subjects increased their eliciting dose by at least two doses of the double-blind, placebo-controlled food challenge at month 12, compared to 23.4% in the placebo group.24% of subjects on placebo decreased their eliciting dose between the baseline and month 12 double-blind, placebo-controlled food challenge, compared to only 6.4% of treated subjects.All sensitivity analyses were statistically significant with the 95% CI exceeding the lower bound prespecified threshold of 15%, ranging from 22.1% to 27.8%, confirming the robustness of the primary endpoint analysis.In both baseline eliciting dose (ED) strata, a significantly greater proportion of children treated with the VIASKIN® Peanut Patch were treatment responders as compared to the placebo group. Among children with a baseline ED ≤ 30mg, 49.3% were responders versus 14.7% in the placebo group (△=34.6%; 95% CI: 24.93, 44.24). Among children with a baseline ED = 100mg, 43.1% were responders versus 14.6% in the placebo group (△=28.5%; 95% CI: 17.51, 39.5). The VIASKIN® Peanut Patch was well tolerated; the majority of treatment emergent adverse events (TEAEs) were mild local application site reactions, consistent with DBV’s previous Phase 3 studies.
“Building on the statistically significant topline results from the VITESSE Phase 3 study, the additional data presented at this year’s AAAAI Annual Meeting suggest a broad and consistent treatment effect of the VIASKIN® Peanut Patch, regardless of baseline eliciting dose strata or study population analysis,” stated David Fleischer M.D., Professor of Pediatrics at Children’s Hospital Colorado and Global Principal Investigator of the VITESSE study. “The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN® Peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population."

“We believe the additional data presented today demonstrate that the VIASKIN® Peanut Patch consistently induced desensitization among subjects irrespective of study subgroup or baseline characteristics,” stated Pharis Mohideen M.D., Chief Medical Officer of DBV Technologies. “If approved, the VIASKIN® Peanut Patch would provide caregivers with a non-invasive option that fits into daily activities. To that end, these data support a Biologics License Application, which we are planning to submit to FDA in the first half of this year.”

The presentation will be made available on the Scientific Publication & Presentations page on the Company’s website at https://dbv-technologies.com/events/aaaai-annual-meeting-2026/.

*Responders were defined as children with a baseline eliciting dose (ED) ≤30 mg who achieved an ED ≥300 mg of peanut protein at month 12, or children with a baseline ED = 100 mg who achieved an ED ≥600 mg of peanut protein at month 12, as measured by a double-blind, placebo-controlled food challenge (DBPCFC). The ED is the amount of peanut protein that induced an allergic reaction.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN® Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, results of DBV’s clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations with respect to the submission of BLAs to FDA, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

The Company reminds that the going concern assessment is made as of the date of this press release based on management’s current assumptions. In accordance with U.S. GAAP, IFRS, SEC and AMF rules, the Company will update its going‑concern evaluation as of the issuance of its Annual Report on Form 10‑K and the universal registration document.

VIASKIN is a registered trademark of DBV Technologies.

Investor Relations Contact
Jonathan Neely
DBV Technologies
[email protected]

Media Contact
Brett Whelan
DBV Technologies
[email protected]

PDF Version

Nu Holdings (NU 0.50%) has already proven it can grow. In 2025, it delivered strong revenue expansion, rising net income, and solid return on equity.

But growth was never the most challenging part.

The real test now is whether Nu Holdings can withstand a credit cycle without cracking.

Image source: Getty Images.

Growth is easy in a favorable environment Nu Holdings' core profit engine remains consumer lending, particularly unsecured credit in Brazil and, increasingly, in Mexico. When economic conditions are stable, this model scales beautifully.

Loan books expand. Net interest income rises. Delinquencies remain manageable. Returns look impressive.

In 2025, Nu Holdings' loan portfolio surpassed $27 billion and later moved above $30 billion, reflecting strong year-over-year growth. Asset quality metrics remained under control, with delinquency ratios in manageable mid-single-digit ranges.

So far, so good.

But lending performance during expansion tells only part of the story.

Today's Change

(

-0.50

%) $

-0.07

Current Price

$

14.98

The risk in emerging markets Brazil and Mexico offer enormous opportunities. They also carry volatility.

Inflation spikes, currency swings, policy shifts, or economic slowdowns can pressure household balance sheets. Unsecured consumer credit often absorbs that shock first. If unemployment rises or purchasing power weakens, early delinquency indicators can deteriorate rapidly.

The question investors must ask is simple: Can Nu Holdings maintain underwriting discipline if macro conditions tighten?

High return on equity in good times impresses the market. Sustained return on equity through stress builds institutional credibility.

Nu Holdings' digital model and data-driven underwriting give it an advantage. Its low-cost structure also provides flexibility that branch-heavy banks lack. But the company has not yet navigated a full downturn at its current scale.

That test still lies ahead.

Nu Holdings' stock trades at a premium valuation Nu Holdings trades more like a growth fintech than a traditional bank. That premium reflects confidence in durable expansion and disciplined execution. For perspective, the stock has a price-to-earnings (P/E) ratio of 31.

If credit performance holds steady, that confidence may prove justified. If asset quality weakens meaningfully, earnings could compress quickly. High-multiple stocks rarely react kindly to sudden earnings volatility.

This is why the credit cycle matters so much. It is not just an operational risk. It is a valuation risk.

What does it mean for investors? Nu Holdings is transitioning from disruptor to dominant financial platform. As scale increases, expectations rise. Investors no longer need proof that Nu Holdings can add customers. They need evidence that it can defend margins and protect capital during stress.

If Nu Holdings can navigate a more challenging macro environment while preserving asset quality and profitability, it will solidify its position as a resilient regional banking leader -- not just a high-growth fintech success story.

Investors will be keeping a close eye on the next down cycle (which could happen in 2026) to gauge whether the company can do just that.

Anthropic's Claude artificial intelligence assistant app jumped to the No. 2 slot on Apple's chart of top U.S. free apps late on Friday, hours after the Trump administration sought to block government agencies' adoption of the startup's technology.

The rise in popularity suggests that Anthropic is benefiting from its presence in news headlines, stemming from its refusal to have its models used for mass domestic surveillance or for fully autonomous weapons.

"The Leftwing nut jobs at Anthropic have made a DISASTROUS MISTAKE trying to STRONG-ARM the Department of War, and force them to obey their Terms of Service instead of our Constitution," President Donald Trump wrote in a Friday Truth Social post.

Department of Defense Secretary Pete Hegseth said he asked that Anthropic be labeled as a supply-chain risk to national security, and therefore, no U.S. defense contractor would be able to draw on Anthropic tools.

"It is the Department's prerogative to select contractors most aligned with their vision," Anthropic CEO Dario Amodei said in a statement. "But given the substantial value that Anthropic's technology provides to our armed forces, we hope they reconsider."

Historically, other AI chat apps have been more popular among consumers than Claude. OpenAI's ChatGPT sat at No. 1 on the App Store rankings on Saturday, while Google's Gemini was at No. 3.

The Claude iOS app has gained momentum this month. On Jan. 30, it was ranked No. 131 in the U.S., and it bounced between the top 20 and the top 50 for much of February, according to data from analytics company Sensor Tower. The data shows ChatGPT has held on to the No. 1 spot for most of February.

In the past year, Anthropic — which was formed in 2021 by former OpenAI employees — has gained momentum as a supplier of models for coding and general corporate use. OpenAI, whose ChatGPT now has over 900 million weekly users, has been responding to Anthropic's surge in business by striking partnerships with consulting firms such as Accenture and Capgemini.

On Friday night, OpenAI CEO Sam Altman said the startup had reached an agreement with the U.S. Defense Department on the deployment of its models.

Hours later, pop singer Katy Perry posted a screenshot of Anthropic's Pro subscription for consumers, with a heart superimposed over it.

watch now

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) - including comparison of the Pivotal Study results to the ENROLL-HD external historical data set- was not fully approved by the U.S. Food and Drug Administration (the "FDA"); (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application ("BLA") timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants' statements about uniQure's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285697

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, Feb. 28, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Restaurant Brands International Inc. (QSR) Analyst/Investor Day Transcript

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of KDDI Corporation (OTC PINK: KDDIY) resulting from allegations that KDDI may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased KDDI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=52883 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On February 6, 2026, KDDI posted an announcement on its website entitled "Notice Regarding Expectation that Disclosure of Earnings Report for the Third Quarter of the Fiscal Year Ending March 2026 Will Exceed the 45-Day Period Following the End of Such Quarter." The announcement stated that KDDI has "decided to postpone the disclosure of its earnings report" and that the reason for postponement was due to uncertainties regarding the quarterly results, in light of a previously announced internal investigation.

On this news, KDDI American Depositary Receipts (under the ticker symbol "KDDIY") fell 11.4% on February 6, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285699

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

A near 50% discount and a 17% yield look irresistible.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Dima Zel / Shutterstock.com

Headquartered in Texas, Intuitive Machines (NASDAQ:LUNR), an American space exploration company, is trading at $17.67, down 4% over the past month even after a $175 million equity raise priced at $15.12 per share hit shareholders hard. Reddit sentiment has tracked that arc: a quarterly average of 70.2 (bullish) has cooled to a weekly average of 57.7 (neutral) as the market weighs whether Intuitive Machines is executing a genuine infrastructure pivot or overleveraging on ambition.

The Lanteris Deal That Changed Everything for LUNR If you keep a close eye on overall sentiment, it peaked at 88 (very bullish) on February 14 after Intuitive Machines closed its $800 million acquisition of Lanteris Space Systems in mid-January, structured as $450 million in cash and $350 million in stock. The deal transforms the company from a lunar lander operator into a vertically integrated platform spanning low-Earth orbit, cislunar space, and eventually Mars. CEO Steve Altemus called it a direct entry into “multi-billion-dollar space programs.”

Unfortunately, the financial reality is harder to ignore: Intuitive Machines posted Q3 2025 revenue of $52.4 million, a net loss of $10 million, and adjusted EBITDA of negative $13.2 million. Shares outstanding expanded from 25.6 million in 2023 to 117.8 million by Q3 2025, a 360% increase, with the latest raise adding more. The stock trades at 11x trailing revenue, compared to a sector median closer to 2x, a premium that requires the integration thesis to actually deliver.

Reddit Is Watching the Dilution Math Discussion on r/stocks and r/wallstreetbets has cooled from peak enthusiasm, with three concerns dominating:

The $175 million raise was priced at $15.12 per share, triggering a 15.93% premarket drop on announcement day The company carries $371 million in total debt against accumulated losses of negative $397 million The combined entity targets over $850 million in annual revenue, but that remains a forward projection A post on r/stocks titled “Good buy the dip opportunities: Tempus AI & LUNR?” drew 49 upvotes and 38 comments, with users debating — not endorsing — the implications of the post-raise selloff and the company’s dilution trajectory going forward. On r/wallstreetbets, a post titled “LUNR YOLO” captured peak enthusiasm during the quarter. The r/wallstreetbets post “LUNR YOLO” drew 182 upvotes and 115 comments. A separate post titled “Full ported my FHSA, thanks LUNR” also drew 147 upvotes and 46 comments on r/wallstreetbets during the same period, with the post itself reading:

“Full ported my FHSA, thanks LUNR”

This infographic details Intuitive Machines’ (LUNR) investment profile, recent social sentiment, and the primary factors influencing investor mood as of February 27, 2026. Good buy the dip opportunities: Tempus AI & LUNR?
by r/stocks in stocks LUNR YOLO
by r/wallstreetbets in wallstreetbets Full ported my FHSA, thanks LUNR
by r/wallstreetbets in wallstreetbets Analyst Conviction vs. Execution Risk Looking ahead, Cantor Fitzgerald holds an Overweight rating with a $16 price target, and seven of nine covering analysts rate LUNR a Buy, with a consensus target of $18.89. The price target range spans $9.50 to $26.00, a 174% spread reflecting genuine disagreement about whether the pivot is credible. CEO Steve Altemus sold $31.5 million in stock in December 2025 and another $9 million in early January 2026 under pre-established trading plans, adding noise to an already uncertain picture. For now, all eyes will be on the NASA Lunar Terrain Vehicle contract decision, which remains the key catalyst that could validate or deflate the prime contractor thesis in a single announcement.

Simply Good Foods (SMPL) shares fell 54% over the past year to $17.05. Founder Joe Scalzo returned as CEO on January 19.

Simply Good Foods CFO bought $199K in shares. Scalzo received 2M stock options upon his return.

Reddit sentiment for Simply Good Foods rose from 60 to 72 out of 100 driven by the insider buying activity.

Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.(Sponsor)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Kathryn Koehler/Courtesy of 24/7 Wall St.

A consumer packaged food and beverage company, Simply Good Foods (NASDAQ:SMPL) has shed roughly 54% of its value over the past year, with shares sitting at $17.05 against a 52-week high of $38.16. Retail sentiment on Reddit has stabilized at a bullish 72 out of 100, driven almost entirely by one catalyst: founder Joe Scalzo’s return as CEO on January 19, 2026, one day after Geoff Tanner was removed. The question the market now has to wrestle with is whether Scalzo is a genuine turnaround architect or a bridge leader parachuting into a structurally broken portfolio.

Reddit sentiment for SMPL rose from approximately 60 to a bullish 72 out of 100 between January 19 and February 21, 2026, driven by the founder return narrative and insider buying activity.

This infographic details the factors driving Simply Good Foods’ (SMPL) bullish Reddit sentiment, including the founder’s return as CEO and significant insider stock activity. As of Friday, February 27, 2026, the sentiment score is 72/100, stable month-over-month. The Insider Signal Driving SMPL Bullishness A single post in r/stocks, published February 21, 2026 by u/stockist420, has accumulated 122 upvotes and 25 comments within days. The post’s framing cuts to the core of the bull thesis: “CEO got fired, founder came back with 2M stock options, CFO bought $199K, a congressman bought too.”

CEO got fired, founder came back with 2M stock options, CFO bought $199K, a congressman bought too. Here’s what I found digging into SMPL
by u/stockist420 in stocks Top Gaining Stocks

Top Losing Stocks